ClinicalTrials.gg

Program

hetrombopag olamine

Also written as “Hetrombopag Olamine”, “Herombopag Olamine Tablets” and “Hetrombopag Olamine Tablet”.

Its studies are mostly in Anemia, Aplastic · Purpura, Thrombocytopenic, Idiopathic · Thrombocytopenia, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Jul 18, 201715 company-led studies, 4 open or runningNext primary completion: Dec 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine154 open or runningphase 3since Jul 18, 2017Dec 25, 2012Dec 2028phase 3 · NCT07286032

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 25, 2012First study: phase 1 study in HealthyFirst studyNCT01830660 · 96 enrolled · China
  2. Mar 20, 2015Phase 1 study in Purpura, Thrombocytopenic, IdiopathicNCT02403440 · 24 enrolled · China
  3. Apr 1, 2015Phase 1 study in HealthyNCT02409394 · 12 enrolled · China
  4. Nov 19, 2015Phase 1 study in Chronic Idiopathic Thrombocytopenic PurpuraNCT02614846 · 29 enrolled · China
  5. Jul 18, 2017Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT03222843 · 424 enrolled · China
  6. Jun 3, 2018Phase 2 study in Anemia, AplasticNCT03557099 · 55 enrolled · China
  7. Jun 18, 2018Phase 1 study in Purpura, Thrombocytopenic, IdiopathicNCT03603132 · 15 enrolled · China
  8. Jan 30, 2019Phase 3 study in Anemia, AplasticNCT03825744 · 240 enrolled · China
  9. May 5, 2019Phase 1 study in HealthyNCT03977805 · 6 enrolled · China
  10. Jul 12, 2021Phase 3 study in Treatment-naive Severe Aplastic AnemiaNCT04961710 · 157 enrolled · China
  11. Oct 12, 20212 phase 1 studies in Sever Aplastic AnaemiaNCT05088655, NCT05088642
  12. Sep 1, 2023Phase 1 study in Adult Patients With Chronic Primary ITPNCT06062680 · 15 planned
  13. Mar 29, 2024Phase 1 study in Adult Patients With Chronic Primary ITPNCT06346925 · 18 planned · China
  14. Dec 10, 2025Phase 3 study in Patients With Chemotherapy-Induced ThrombocytopeniaNCT07286032 · 150 planned · United States, Bulgaria, China and more

Ahead

  1. Dec 2028Primary completion: phase 3 study in Patients With Chemotherapy-Induced ThrombocytopeniaNCT07286032

TargetBeta

MPL →read by rule
“Thrombopoietin receptor agonist”ChEMBL 37, by rule

Other programs on MPL

ProgramCompanyFurthest phaseStudies
eltrombopagruleGlaxoSmithKlinephase 449
romiplostimruleAmgenphase 438
avatrombopagruleEisaiphase 425

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07286032Patients With Chemotherapy-Induced Thrombocytopenia · United States, Bulgaria, China and more3RecruitingDec 2028150
NCT06346925Adult Patients With Chronic Primary ITP · China1Not yet recruitingJul 202418
NCT06062680Adult Patients With Chronic Primary ITP1Not yet recruitingNov 15, 202315
NCT05088655Sever Aplastic Anaemia · China1CompletedJul 25, 202258
NCT05088642Sever Aplastic Anaemia · China1CompletedDec 4, 202024
NCT04961710Treatment-naive Severe Aplastic Anemia · China3Active, not recruitingNov 30, 2024157
NCT03977805Healthy · China1CompletedJun 13, 20196
NCT03825744Anemia, Aplastic · China3CompletedJul 3, 2024240
NCT03603132Purpura, Thrombocytopenic, Idiopathic · China1CompletedAug 17, 201815
NCT03557099Anemia, Aplastic · China2CompletedOct 31, 201955
NCT03222843Purpura, Thrombocytopenic, Idiopathic · China3CompletedNov 11, 2019424
NCT02614846Chronic Idiopathic Thrombocytopenic Purpura · China1UNKNOWNMar 201629
NCT02409394Healthy · China1CompletedApr 201412
NCT02403440Purpura, Thrombocytopenic, Idiopathic · China1UNKNOWNApr 201524
NCT01830660Healthy · China1CompletedJun 201396

How it is read

Names in the registry

  • “Hetrombopag Olamine”, 9 entries
  • “Herombopag Olamine Tablets”, 2 entries
  • “Hetrombopag Olamine Tablet”, 2 entries
  • “Hetrombopag Olamine+Standard Therapy”, 1 entry
  • “Hetrombopag Olamine Tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.